Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors

Author： Joshi Ashish V.   Stephens Jennifer M.   Munro Vicki   Mathew Prasad   Botteman Marc F.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.22, Iss.1, 2006-01, pp. : 23-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors

By Knight Chris  

Advances in Therapy, Vol. 26, Iss. 1, 2009-01 ,pp. : 68-88

Springer Publishing Company

Access to resources Recommend Favorite

Recombinant Factor VIIa Reduces Bleeding Risk in Patients on Platelet Aggregation Inhibitors Immediately prior to Renal Transplantation – A Retrospective Analysis

By  

Urologia Internationalis, Vol. 78, Iss. 2, 2007-02 ,pp. : 135-139

Karger

Access to resources Recommend Favorite

Treatment of Bleeding in Patients with Platelet Disorders: Is There a Place for Recombinant Factor VIIa?

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 1, 2002-05 ,pp. : 37-40

Karger

Access to resources Recommend Favorite

Factor VIII Inhibitors in Patients with Hemophilia A

By  

Acta Haematologica, Vol. 102, Iss. 1, 1999-09 ,pp. : 42-46

Karger

Access to resources Recommend Favorite

The Evidence behind Inhibitor Treatment with Recombinant Factor VIIa

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 1, 2002-05 ,pp. : 13-18

Karger

Access to resources Recommend Favorite